ASP Isotopes (ASPI)
Develops isotope-enrichment technology across specialist isotopes, nuclear fuels, radiopharmacy, and helium.
$3.21
After hours+0.04 (+1.10%)
At close$3.18(−0.16%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 17 | 4 | 5 |
| Cost of revenue | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 15 | 3 | 4 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 2 | 1 |
| 4 | 4 | 6 | 8 | 6 | 8 | 8 | 13 | 15 | 24 | 27 | 36 | |
| Research & development | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 3 | 7 | 5 | 7 |
| 4 | 4 | 6 | 7 | 5 | 7 | 7 | 12 | 12 | 18 | 21 | 29 | |
| General & administrative | 4 | 4 | 6 | 7 | 5 | 7 | 7 | 12 | 12 | 18 | 21 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −4 | −4 | −6 | −7 | −5 | −8 | −8 | −12 | −15 | −22 | −25 | −34 |
| 0 | 0 | −1 | −1 | −2 | −1 | −1 | −63 | 2 | −41 | −2 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 4 | 3 | 3 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Other non-operating income | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 63 | −2 | 41 | 0 | 0 |
| Income before tax | −4 | −4 | −7 | −9 | −7 | −9 | −9 | −75 | −13 | −63 | −27 | −34 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −4 | −4 | −7 | −9 | −7 | −9 | −8 | −75 | −13 | −63 | −27 | −34 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 0 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −4 | −4 | −7 | −9 | −7 | −9 | −8 | −75 | −13 | −79 | −7 | −34 |
| EPS, basic | −$0.14 | −$0.09 | −$0.16 | −$0.24 | −$0.12 | −$0.16 | −$0.12 | −$1.03 | −$0.15 | −$0.84 | −$0.06 | −$0.27 |
| EPS, diluted | −$0.14 | −$0.09 | −$0.16 | −$0.24 | −$0.12 | −$0.16 | −$0.12 | −$1.03 | −$0.15 | −$0.84 | −$0.06 | −$0.27 |
| Weighted average shares, basic | 31 | 47 | 45 | 49 | 62 | 71 | 69 | 73 | 89 | 94 | 121 | 123 |
| Weighted average shares, diluted | 31 | 47 | 45 | 49 | 62 | 71 | 69 | 73 | 89 | 94 | 121 | 123 |
| EBITDA | −4 | −4 | −7 | −9 | −7 | −9 | −8 | −74 | −12 | −62 | −22 | −33 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 1 |
| EBIT | −4 | −4 | −7 | −9 | −7 | −9 | −8 | −75 | −13 | −63 | −25 | −34 |
